TrialThe oncologist2018

NGR-hTNF and Doxorubicin as Second-Line Treatment of Patients with Small Cell Lung Cancer.

Vanesa Gregorc et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.